Basilea Pharmaceutica Ltd announced an 11% increase in total revenue and a 15% rise in royalty income for the financial year ended December 31, 2025. The company’s net cash position tripled, and its Phase 3 program for fosmanogepix is progressing as planned. Financial guidance for FY 2026 includes a double-digit increase in total revenue and operating profit.

CEO David Veitch highlighted Basilea’s transformation towards treating severe bacterial and fungal infections, leading to consistent growth and a strong R&D pipeline. The company aims to have four commercial assets by 2030 and a broad R&D portfolio for long-term growth. CFO Adesh Kaul emphasized the company’s robust financial performance in 2025, with increased revenue and a strengthened balance sheet.

In 2025, Basilea reported CHF 232.4 million in total revenue, with royalty income reaching CHF 111.6 million. The company invested CHF 105.9 million in R&D, focusing on phase 3 studies of fosmanogepix and in-licensing ceftibuten-ledaborbactam. Operating profit was CHF 51.5 million, with a net profit of CHF 40.2 million.

Basilea’s positive net cash flow of CHF 62.1 million in 2025 allowed for a 30% increase in cash, cash equivalents, and restricted cash to CHF 162.3 million by December 31. The company also repurchased CHF 21.1 million in senior unsecured convertible bonds, reducing total financial debt since 2022 by approximately CHF 145 million. Basilea Pharmaceutica Ltd reported a 15% increase in royalty income and an 11% increase in total revenue, with tripled net cash position and a Phase 3 program progressing as planned. Financial guidance for FY 2026 includes a double-digit increase in total revenue and operating profit. Conference call and webcast scheduled for today at 4 p.m. (CET).

Key financial figures for FY 2025 show total revenue of CHF 232.4 million, with operating profit at CHF 51.5 million. Net cash position increased to CHF 86.9 million as of December 31, 2025.

Basilea provides financial guidance for FY 2026, expecting a 10% increase in total revenue and a 20% increase in operating profit. The company aims to launch two new products by 2030, with plans to support growth and value creation beyond current key products.

The company expects to maintain strong sales growth for Cresemba, offsetting potential challenges from the Swiss Franc and decreases in product revenue from partners. Basilea plans to increase R&D investments in key value drivers while improving operating profitability.

Basilea aims to add CHF 600 million in cumulative cash flows from Cresemba and Zevtera over the next five years. The company also has potential non-dilutive R&D funding available to support development of key products.

The board of directors has nominated new members Anne Whitaker and Dr. Naseem Amin, with experienced executives stepping down to make way for new leadership. The company looks to continue its growth trajectory with a focus on innovation and financial strength. Basilea Pharmaceutica Ltd announces a 15% increase in royalty income and an 11% increase in total revenue, with a tripled net cash position. The Phase 3 program with fosmanogepix is progressing as planned, with financial guidance for FY 2026 indicating a double-digit increase in total revenue and operating profit.

Anne Whitaker has an extensive background in the pharmaceutical industry, having held leadership positions at various companies. She currently serves on the boards of several organizations and is an advisor at New Vale Capital LLC. Naseem Amin, M.D., also has a strong industry background and currently serves as director and CEO of Orphalan SA.

Basilea Pharmaceutica Ltd will host a conference call and webcast today to discuss financial and operating results. The live audio webcast can be accessed online, and phone details are provided for those wishing to ask questions. A replay of the webcast will also be available online shortly after the event.

Save the date for Basilea Capital Markets Day on October 28, 2026, in Zurich. This event will provide updates on the company’s strategic direction and value drivers, featuring presentations from senior management and external experts. Basilea is a Swiss biopharmaceutical company committed to developing innovative drugs for severe infections.

Read more at GlobeNewswire: Basilea reports strong 2025 full-year results, surpassing